Parkinson's disease and microRNAs - Lessons from model organisms and human studies
Parkinson's disease (PD) is a progressive, age-associated neurodegenerative disorder that affects an estimated 10 million people worldwide. PD is characterized by proteinaceous, cytoplasmic inclusions containing α-synuclein, called Lewy Bodies, which form in dopaminergic neurons in an age-depen...
Saved in:
| Published in: | Experimental gerontology Vol. 155; p. 111585 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Inc
01-11-2021
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Parkinson's disease (PD) is a progressive, age-associated neurodegenerative disorder that affects an estimated 10 million people worldwide. PD is characterized by proteinaceous, cytoplasmic inclusions containing α-synuclein, called Lewy Bodies, which form in dopaminergic neurons in an age-dependent manner, and are associated with the emergence of characteristic PD symptoms such as resting tremor, rigidity, slow movements and postural instability. Although considerable progress has been made in recent years in identifying genetic and environmental factors that are associated with PD, early diagnosis and therapeutic options remain severely lacking. Recently, microRNAs (miRNAs) have emerged as novel therapeutic targets in various diseases, such as cancer and neurodegenerative diseases. MiRNAs have been shown to play roles in various aging and neurodegenerative disease models across phyla. More recently, studies have identified specific roles for miRNAs and their targets in the pathogenesis and progression of PD in several model organisms. Here, we discuss the evolving field of miRNAs, their association with PD, and the outlook for the future.
•Expression studies have identified differentially regulated miRNAs and targets associated with Parkinson's Disease (PD).•In animal models of PD, mutations in specific miRNAs have been shown to affect pathogenesis relevant to PD.•Functional studies in animal models identify miRNAs that may regulate stress response pathways associated with PD.•Conserved miRNAs and associated gene targets represent novel targets for future therapeutic approaches in PD. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 Present Address: Blackstone Valley Pediatrics, 2 Meehan Ln, Cumberland, RI, 02864. Present Address: Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. |
| ISSN: | 0531-5565 1873-6815 |
| DOI: | 10.1016/j.exger.2021.111585 |